Royalty Pharma plc (RPRX)
NASDAQ: RPRX · IEX Real-Time Price · USD
27.27
-0.61 (-2.19%)
At close: May 17, 2024, 4:00 PM
27.56
+0.29 (1.06%)
After-hours: May 17, 2024, 7:15 PM EDT
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 46.75, with a low estimate of 38 and a high estimate of 57. The average target predicts an increase of 71.43% from the current stock price of 27.27.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 12, 2024.
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 1 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +39.35% | Apr 12, 2024 |
JP Morgan | JP Morgan | Buy Maintains $45 → $42 | Buy | Maintains | $45 → $42 | +54.02% | Feb 20, 2024 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $56 → $50 | Strong Buy | Maintains | $56 → $50 | +83.35% | Feb 20, 2024 |
Morgan Stanley | Morgan Stanley | Buy Maintains $54 → $57 | Buy | Maintains | $54 → $57 | +109.02% | Nov 9, 2023 |
Morgan Stanley | Morgan Stanley | Buy Maintains $53 → $54 | Buy | Maintains | $53 → $54 | +98.02% | Oct 11, 2023 |
Financial Forecast
Revenue This Year
2.68B
from 2.35B
Increased by 13.74%
Revenue Next Year
2.93B
from 2.68B
Increased by 9.41%
EPS This Year
3.85
from 2.53
Increased by 52.11%
EPS Next Year
4.20
from 3.85
Increased by 9.24%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 2.9B | 3.4B | 3.8B | 3.1B | 3.3B |
Avg | 2.7B | 2.9B | 3.2B | 3.0B | 3.2B |
Low | 2.3B | 2.5B | 2.8B | 2.9B | 3.1B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 24.5% | 26.5% | 29.4% | -3.9% | 8.3% |
Avg | 13.7% | 9.4% | 10.7% | -6.7% | 5.2% |
Low | -0.4% | -6.0% | -4.8% | -10.3% | 1.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 4.40 | 4.98 | 5.59 | 6.21 | 7.06 |
Avg | 3.85 | 4.20 | 4.60 | 6.03 | 6.85 |
Low | 2.91 | 2.74 | 2.91 | 5.79 | 6.59 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 73.9% | 29.3% | 32.9% | 35.0% | 17.0% |
Avg | 52.1% | 9.2% | 9.3% | 31.1% | 13.7% |
Low | 15.0% | -28.7% | -30.8% | 26.0% | 9.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.